Background: Gastrointestinal Stromal Tumors (GIST) are mesenchymal malignancies in GI tract. GIST resistant to imatinib therapy are widely reported. Epidermal Growth Factor Receptor (EGFR) plays a role in progressivity of malignancy. This study aimed at analyzing the expression of EGFR on GIST that leads to the probability of using Anti-EGFR as a substitutive therapy for Imatinib-resistance GIST.
Methods: This study performed in Dr. Soetomo General Hospital in CD-117 positive GIST from 2009 to 2014. The number of the samples were 39, samples were measured using semi quantitative method, and analyzed using Spearman formula.
Results: CD-117 positive GIST showed EGFR expression in 74.4% samples, Correlation between EGFR expression with the tumor size (p=0.129) and mitotic index (p=0.626).
Conclusion: CD-117 positive GIST showed EGFR expression in 74.4% samples, though there was no significant correlation between EGFR expression with tumor size (p=0.129) and mitotic index (p=0.626).
How to cite this article:
Vicky S Budipramana, Syahfreadi, Dyah Fauziah. Correlation between GIST positive CD117 with EGFR expression based on tumor size and mitotic index. Int J Clin Diagn Pathol 2019;2(2):85-89. DOI: 10.33545/pathol.2019.v2.i2b.83
